Bringing patients into focus
with ocular gene therapy
Atsena Therapeutics is conducting clinical trials for inherited retinal diseases with our investigational gene therapies.
Atsena is evaluating ATSN-101 in an ongoing Phase I/II clinical trial (clinicaltrials.gov identifier: NCT03920007) in patients with GUCY2D-associated Leber congenital amaurosis (LCA1). Learn more about the clinical trial here: https://clinicaltrials.gov/ct2/show/NCT03920007
This study is active, but no longer recruiting.
Atsena is leveraging one of its novel spreading capsids, AAV.SPR, in a Phase I/II clinical trial (ClinicalTrials.gov Identifier: NCT05878860) to evaluate ATSN-201 for X-linked retinoschisis (XLRS). Learn more about the clinical trial here: https://www.clinicaltrials.gov/ct2/show/NCT05878860
This study is active and recruiting.
Contact us with questions at email@example.com
All of Atsena’s gene therapy products are investigational. Safety and efficacy have not been established by the FDA or other regulatory bodies.